Two Years Since Sickle Cell Miracle Cure, Most Patients Still Waiting

A promising gene therapy for sickle cell disease, approved two years ago, remains largely inaccessible due to limited treatment centers, complex approval processes, and high costs, especially impacting rural and low-income populations despite recent federal initiatives to improve access.